These approaches include either endogenous stimulation of the NK cells in patients, such as administration of cytokines to activate NK cells in cancer patients and treatment of the patients with antibodies that target the NK inhibitor receptor or checkpoint protein to activate NK cells or agonist of NK cell activating receptors, or adoptive NK cell transfer to the cancer patients. This evidence concerns the gene NCR2 and cancer.